---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-034204"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T21:27:22.116068+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immuneering doses first patient in Phase 2a of IMM-1-104; Phase 1 data shows safety and biomarker activity

## Summary
- First patient dosed in Phase 2a of IMM-1-104; ~150 patients planned across 5 arms (monotherapy and combination).
- Phase 1 (N=41): no grade 4 TRAEs; only one grade 3 (reversible rash); most common grade 1/2: diarrhea 19.5%, nausea 19.5%.
- At 320mg, pERK inhibition ≥90% for 2.7h; 100% of evaluable patients (N=22) showed no new RAS or MAPK pathway mutations by ctDNA.
- 53% of patients had ≥1 target lesion regression at 240/320mg; best individual regression -35.7% at 320mg in second-line.
- Thomas J. Schall, Ph.D. appointed to Board of Directors as Class I Director effective March 11, 2024.

## SEC filing metadata
- accession: 0001104659-24-034204
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000110465924034204/0001104659-24-034204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000110465924034204/tm248799d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-034204
- JSON: https://secwatch.observer/filing/0001104659-24-034204.json
- Plain text: https://secwatch.observer/filing/0001104659-24-034204.txt

## Key facts
- Executive change
  Thomas J. Schall, Ph.D. was appointed as Director at Immuneering Corp.
  - Action: appointed
  - Role: Director
  source text: On March 11, 2024, the Board of Directors of Immuneering Corporation (“we,” “our” and “us”) appointed Thomas J. Schall, Ph.D. to serve as a member of our Board of Directors as a Class I Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000110465924034204/0001104659-24-034204-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.